ReviewScientifica2013
Current and future therapies for multiple sclerosis.
Review in Scientifica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 71 citations in OpenAlex.
- Review
- Evaluating the risk of digestive system cancer in autoimmune disease patients: a systematic review and meta-analysis focusing on bias assessment.EClinicalMedicine · 2025Article
- Remyelination as a therapeutic target in the treatment of multiple sclerosis.AIMS neuroscience · 2025Review
- Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine.Pharmaceutics · 2024Review
- Neurorehabilitation in Multiple Sclerosis-A Review of Present Approaches and Future Considerations.Journal of clinical medicine · 2022Review
- The effect of Ccnb1ip1 insulator on monoclonal antibody expression in Chinese hamster ovary cells.Molecular biology reports · 2022Article
- Modulating the Ubiquitin-Proteasome System: A Therapeutic Strategy for Autoimmune Diseases.Cells · 2022Review
- Piperine Improves Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats Through its Neuroprotective, Anti-inflammatory, and Antioxidant Effects.Molecular neurobiology · 2021Article
- The pattern of thyroiditis in multiple sclerosis: a cross-sectional study in a tertiary care hospital in Egypt.The Egyptian journal of internal medicine · 2020Article
- A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial.Noro psikiyatri arsivi · 2019Article
- Nasal delivery of Fasudil-modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis.CNS neuroscience & therapeutics · 2019Article
- Tocopherol Emulsions as Functional Autoantigen Delivery Vehicles Evoke Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis.Molecular pharmaceutics · 2019Article
- Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.International journal of physiology, pathophysiology and pharmacology · 2019Review
- Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.International journal of physiology, pathophysiology and pharmacology · 2019Review
- Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis.Stem cell investigation · 2019Review
- The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.Neuropharmacology · 2017Review
- Prolonged stimulation of a brainstem raphe region attenuates experimental autoimmune encephalomyelitis.Neuroscience · 2017Article
- Oriental Medicine Samhwangsasim-tang Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Th1 Cell Responses and Upregulating Treg Cell Responses.Frontiers in pharmacology · 2017Article
- Immune-mediated processes in neurodegeneration: where do we stand?Journal of neurology · 2016Review
- Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling study.Therapeutic advances in neurological disorders · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the introduction of interferon- β 1b in 1993 as the first FDA-approved treatment for multiple sclerosis, the era of treatment of this incurable disease began, and its natural course was permanently changed. Currently, seven different treatments for patients with multiple sclerosis with different mechanisms of action and dissimilar side effect profiles exist. These medications include interferon- β 1a intramuscular (Avonex), interferon- β 1a subcutaneous (Rebif), interferon- β 1b subcutaneous (Betaseron/Extavia), glatiramer acetate (Copaxone), natalizumab (Tysabri), fingolimod (Gilenya), teriflunomide (Aubagio), and mitoxantrone (Novantrone). In addition, a large number of clinical trials are being conducted to assess the safety and efficacy of various experimental agents in patients with multiple sclerosis, including alemtuzumab, dimethyl fumarate, laquinimod, rituximab, daclizumab, and cladribine. In this paper, the author presents a concise and comprehensive review of present and potential treatments for this incurable disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.